Adaptimmune

its TCR-T product Tecelra (afamitresgene autoleucel) targets MAGE-A4 in synovial sarcoma and was the first engineered-TCR cell therapy approved, anchoring the autologous TCR-T class alongside pipeline assets lete-cel (NY-ESO-1) and other MAGE-A4/PRAME programmes.

Country: United Kingdom
Ticker: ADAP

Commercial TCR-T (Tecelra)

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	$55 million upfront payment from US WorldMeds plus up to $30 million in milestone payments, following the sale of its cell therapy assets (TECELRA, lete-cel, afami-cel, uza-cel) in July 2025	adaptimmune.com · sec.gov
Capacity	Commercial manufacturing success rate of 100% with no constraints as of the second quarter of 2025	adaptimmune.com · newsfilecorp.com · sec.gov
Regulatory approval	TECELRA (afamitresgene autoleucel) received U.S. FDA accelerated approval on August 1, 2024 for adults with unresectable or metastatic synovial sarcoma	adaptimmune.com · cancer.gov · fda.gov
Production site	Facilities in Philadelphia, Boston, and the United Kingdom	adaptimmune.com · newsfilecorp.com
Headcount	Reduced workforce by approximately 29% in the first quarter of 2025 and planned a further reduction of approximately 62% of the remaining workforce following the July 2025 transaction	adaptimmune.com · sec.gov
Revenue	Product revenue of $11.1 million for the second quarter of 2025; total revenue of $13.7 million for the same period	sec.gov

Independent sources: cancer.gov · fda.gov · newsfilecorp.com · sec.gov

Technologies

Name	Cluster	Risk
TCR therapy (T-cell receptor engineered T cells)	therapeutics-platforms	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.